articleJournal of Clinical OncologyApr 19, 2022BRONZE OA

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

FAFabrice AndreNINofisat IsmailaKHKimberly H. AllisonWEWilliam E. BarlowDEDeborah E. Collyar

Institut Gustave Roussy · American Society of Clinical Oncology · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

PURPOSE To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer. METHODS An updated literature search identified randomized clinical trials and prospective-retrospective studies published from January 2016 to October 2021. Outcomes of interest included overall survival and disease-free or recurrence-free survival. Expert Panel members used informal consensus to develop evidence-based recommendations. RESULTS The search identified 24 studies informing the evidence base. RECOMMENDATIONS Clinicians may use Onco type DX, MammaPrint, Breast Cancer Index (BCI), and EndoPredict to guide adjuvant endocrine…

Citation impact

341
total citations
FWCI
29.66
Percentile
100%
References
84
Citations per year

Authors

16
  • FA
    Fabrice AndreCorresponding

    Institut Gustave Roussy

  • NI
    Nofisat Ismaila

    American Society of Clinical Oncology

  • KH
    Kimberly H. Allison

    Stanford Medicine, Stanford University

  • WE
    William E. Barlow

    Cancer Research And Biostatistics

  • DE
    Deborah E. Collyar

    Advocates for Youth

Topics & keywords

Topics
Keywords
  • Breast cancer
  • Guideline
  • Adjuvant
  • Chemotherapy
  • Endocrine system
  • Estrogen receptor
  • Adjuvant chemotherapy
  • Disease
No related works found for this paper.

Funding